Skip to content

Tarsus Pharmaceuticals

US · TARS #2389 by market cap Listed 2020
73.01 -4.66 -6.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
  • Total institutional ownership fell 5.4 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
108.11% -5.42pp
Institutions
323 +3
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund61.11%
Hedge Fund23.71%
VC/PE Fund9.83%
Public Company8.99%
Private Company2.89%
Individual/Insider2.75%
Government Pension Fund0.74%
Endowment Fund0.48%
Insurance Company0.33%

Top holders as of 2026-09-30

BlackRock 7.84% · 3.87M sh
Deep Track Capital, LP 7.44% · 3.67M sh
RTW Investments, LP 6.81% · 3.36M sh
FMR 6.64% · 3.27M sh
Janus Henderson Group plc 5.70% · 2.81M sh
Paradigm Biocapital Advisors LP 5.63% · 2.78M sh
Vanguard Capital Management, LLC 3.81% · 1.88M sh
Morgan Stanley 3.47% · 1.71M sh
Tang Capital Management, LLC 3.57% · 1.57M sh
Morgan Stanley Investment Management Inc. 3.47% · 1.71M sh
Jennison Associates LLC 3.37% · 1.66M sh
Millennium Management LLC 3.25% · 1.43M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 26 buys · 21 sells

NameRoleStake
Bobak Azamian Chairperson & CEO 1.75%
William Link Independent Director 0.19%
Seshadri Neervannan Chief Operating Officer 0.16%
Bryan Wahl General Counsel 0.13%
Aziz Mottiwala Former Chief Commercial Officer 0.12%
Jeffrey S. Farrow CFO & Chief Strategy Officer 0.12%
Dianne Whitfield Chief Human Resources Officer 0.07%
Andrew Goldberg Independent Director 0.04%
Wendy Yarno Lead Independent Director 0.03%
Elizabeth Yeu-Lin Chief Medical Officer 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-02 Neera Clase Chief Commercial Officer Other Derivative Acquisition +6,678 --
2026-11-02 Neera Clase Chief Commercial Officer Other Derivative Acquisition +10,587 $72.64
2026-10-31 Neera Clase Chief Commercial Officer Initial Statement of Beneficial 0 --
2026-09-14 William Link Independent Director Automatic Disposition -12,299 $78.33–80.01
2026-09-14 William Link Independent Director Derivative Exercise and Sale -201 $78.33
2026-09-14 David E. Pyott Independent Director Derivative Exercise and Retained +201 --
2026-09-14 Wendy Yarno Lead Independent Director Derivative Exercise and Retained +302 --
2026-09-03 Bobak Azamian Chairperson & CEO Automatic Disposition -10,000 $90.27–91.27
2026-09-03 Seshadri Neervannan Chief Operating Officer Open Market Disposition -4,564 $85.00
2026-09-03 Elizabeth Yeu-Lin Chief Medical Officer Automatic Disposition -13,953 $85.00–90.00
2026-09-01 Bobak Azamian Chairperson & CEO Automatic Disposition -10,000 $80.06
2026-09-01 Aziz Mottiwala Former Chief Commercial Officer Intent to Sell (Form 144) -8,000 $81.80
2026-09-01 Elizabeth Yeu-Lin Chief Medical Officer Automatic Disposition -11,578 $73.86–80.00
2026-09-01 Elizabeth Yeu-Lin Chief Medical Officer Intent to Sell (Form 144) -5,387 $80.00
2026-09-01 Elizabeth Yeu-Lin Chief Medical Officer Intent to Sell (Form 144) -1,590 $80.00
2026-08-31 Aziz Mottiwala Former Chief Commercial Officer Intent to Sell (Form 144) -77,698 $73.96
2026-08-31 Elizabeth Yeu-Lin Chief Medical Officer Intent to Sell (Form 144) -4,601 $73.86
2026-08-24 Aziz Mottiwala Former Chief Commercial Officer Intent to Sell (Form 144) -81,332 $71.85
2026-08-18 Aziz Mottiwala Former Chief Commercial Officer Intent to Sell (Form 144) -53,043 $72.00
2026-06-24 William Link Independent Director Other Derivative Acquisition +3,223 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

Tarsus Pharmaceuticals discussion 0 comments

Add a comment